[{"from": "human", "value": "What can you tell me about this molecule? [C][C][C][=Branch1][C][=O][O][C@@][Branch2][Ring1][P][C][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring1][#Branch1][C][C][C@H1][C@H1][Ring1][=Branch1][C][C][C][=C][C][=Branch1][C][=O][C][C][C@][Ring1][O][Ring1][#Branch1][C][C][C][=Branch1][C][=O][C][O]"}, {"from": "gpt", "value": "The molecule is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and inflammatory pathways. In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. Clascoterone is also being investigated as a novel treatment for androgenetic alopecia."}]